Insider Selling: Scholar Rock (NASDAQ:SRRK) Director Sells $164,068.22 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Joshua Reed sold 3,053 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the sale, the director owned 19,518 shares of the company’s stock, valued at $1,048,897.32. This trade represents a 13.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Down 0.9%

Shares of NASDAQ:SRRK opened at $56.03 on Thursday. Scholar Rock Holding Corporation has a fifty-two week low of $27.07 and a fifty-two week high of $57.80. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. The firm’s 50-day simple moving average is $48.99 and its 200-day simple moving average is $46.85. The company has a market cap of $6.71 billion, a price-to-earnings ratio of -15.61 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the previous year, the business posted ($0.67) EPS. As a group, equities research analysts predict that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Barclays lifted their price target on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Tuesday, April 21st. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 16th. Wedbush upped their price target on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 1st. Finally, Canaccord Genuity Group began coverage on shares of Scholar Rock in a report on Monday, April 20th. They issued a “buy” rating and a $62.00 price target for the company. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $56.00.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds have recently bought and sold shares of SRRK. Siren L.L.C. raised its holdings in Scholar Rock by 17.0% during the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after purchasing an additional 1,575,008 shares during the last quarter. Redmile Group LLC grew its holdings in Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after purchasing an additional 3,845,775 shares during the last quarter. Wellington Management Group LLP grew its holdings in Scholar Rock by 26.7% in the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock valued at $253,703,000 after purchasing an additional 1,213,541 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Scholar Rock by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after buying an additional 280,538 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Scholar Rock by 7.2% during the 4th quarter. State Street Corp now owns 4,034,434 shares of the company’s stock worth $177,717,000 after buying an additional 271,331 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).